Technical Analysis for PRME - Prime Medicine, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 2.99 | -5.68% | -0.18 |
PRME closed down 5.68 percent on Wednesday, November 20, 2024, on 64 percent of normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Stochastic Buy Signal | Bullish | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 18 hours ago |
| Down 5% | about 22 hours ago |
| Down 3% | about 23 hours ago |
| Fell Below Previous Day's Low | about 23 hours ago |
| Down 2 % | about 23 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Prime Medicine is a biotechnology company committed to delivering a new class of differentiated, one-time, curative genetic therapies to address the widest spectrum of diseases. The company is deploying Prime Editing technology, a versatile, precise, efficient and broad gene editing technology, which is designed to make only the right edit at the right position within a gene. With the theoretical potential to repair approximately 90 percent of known disease-causing genetic mutations across many organs and cell types, medicines based on Prime Editing, if approved, could offer a one-time curative genetic therapeutic option to a broad set of patients.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Disease Emerging Technologies Molecular Biology Medical Genetics Genetic Engineering Gene Editing Gene Editing Technology
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Disease Emerging Technologies Molecular Biology Medical Genetics Genetic Engineering Gene Editing Gene Editing Technology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.86 |
| 52 Week Low | 2.9 |
| Average Volume | 1,814,464 |
| 200-Day Moving Average | 5.49 |
| 50-Day Moving Average | 3.83 |
| 20-Day Moving Average | 3.89 |
| 10-Day Moving Average | 3.72 |
| Average True Range | 0.32 |
| RSI (14) | 31.03 |
| ADX | 22.55 |
| +DI | 16.04 |
| -DI | 31.20 |
| Chandelier Exit (Long, 3 ATRs) | 3.76 |
| Chandelier Exit (Short, 3 ATRs) | 3.85 |
| Upper Bollinger Bands | 4.69 |
| Lower Bollinger Band | 3.10 |
| Percent B (%b) | -0.07 |
| BandWidth | 40.98 |
| MACD Line | -0.19 |
| MACD Signal Line | -0.05 |
| MACD Histogram | -0.1344 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.43 | ||||
| Resistance 3 (R3) | 3.44 | 3.32 | 3.35 | ||
| Resistance 2 (R2) | 3.32 | 3.21 | 3.31 | 3.33 | |
| Resistance 1 (R1) | 3.15 | 3.14 | 3.09 | 3.14 | 3.30 |
| Pivot Point | 3.03 | 3.03 | 3.00 | 3.02 | 3.03 |
| Support 1 (S1) | 2.86 | 2.92 | 2.80 | 2.85 | 2.68 |
| Support 2 (S2) | 2.74 | 2.85 | 2.73 | 2.65 | |
| Support 3 (S3) | 2.57 | 2.74 | 2.63 | ||
| Support 4 (S4) | 2.56 |
